MRS2-H Antibody

What is MRS2 protein and why is it significant in research?

MRS2 is a magnesium transporter protein expressed primarily in mitochondrial inner membranes. It plays a crucial role in mitochondrial magnesium homeostasis and is essential for proper myelination in the central nervous system. Additionally, MRS2 expression serves as a genetic hallmark for embryonic stem cells . The protein contains two adjacent transmembrane domains, with the first domain ending with a characteristic gly-met-asn motif . Research involving MRS2 is particularly relevant to studies of magnesium transport mechanisms, mitochondrial function, and neurological disorders associated with dysregulated magnesium homeostasis.

What epitopes do commercially available MRS2 antibodies typically target?

Most commercial anti-MRS2 antibodies are directed against specific epitopes within the protein structure. Common targets include:

The immunogen sequence (C)DPKHSSVDRSKLH corresponding to amino acid residues 211-223 of rat MRS2 is commonly used for antibody production .

How do I confirm specificity when using MRS2 antibodies?

Specificity confirmation is critical for accurate research outcomes. A recommended approach is to use blocking peptides in parallel experiments. Pre-incubation of the MRS2 antibody with its specific blocking peptide should suppress immunoreactivity if the antibody is specific . For example, immunohistochemical staining of mouse hippocampal CA3 region shows strong MRS2 immunoreactivity in the Pyramidal layer, which is effectively suppressed when the antibody is pre-incubated with MRS2 Blocking Peptide .

What sample types are optimal for MRS2 antibody applications?

Based on validated experimental data, the following samples demonstrate reliable MRS2 detection:

When designing experiments, include appropriate positive controls from these validated tissues and negative controls using blocking peptides .

What are the recommended protocols for Western blot analysis using MRS2 antibodies?

For optimal Western blot results:

• Prepare tissue lysates from testis, kidney, or heart tissues

• Use standard SDS-PAGE protocols with appropriate molecular weight markers

• Apply anti-MRS2 antibody at 1:400 dilution

• Include parallel membranes treated with antibody pre-incubated with blocking peptide

• Use appropriate secondary antibodies (typically anti-rabbit for many commercial MRS2 antibodies)

• Visualize using chemiluminescence or other detection methods

This approach enables detection of specific MRS2 signals while controlling for non-specific binding .

How should I optimize immunohistochemical protocols for MRS2 detection?

For effective immunohistochemical staining:

• Use perfusion-fixed frozen tissue sections (particularly effective for brain tissue)

• Apply anti-MRS2 antibody at approximately 1:100 dilution

• Utilize fluorescent secondary antibodies (e.g., goat anti-rabbit-AlexaFluor-488)

• Counterstain nuclei with DAPI for cellular context

• Include control sections treated with antibody pre-incubated with blocking peptide

This methodology has been validated for detection of MRS2 in hippocampal regions with clear visualization of subcellular distribution patterns .

How do I interpret variable MRS2 expression patterns across different tissues?

Variability in MRS2 expression is biologically significant and reflects tissue-specific functions. When analyzing expression patterns:

• Compare mitochondria-rich tissues (heart, kidney, brain) with tissues having lower mitochondrial density

• Correlate subcellular localization with mitochondrial markers

• Assess expression levels relative to known magnesium-dependent processes in specific tissues

• Consider that MRS2 expression serves as a stem cell marker in certain contexts

Normalizing expression to appropriate housekeeping proteins is essential for quantitative comparisons between tissues.

What are potential sources of false positives when using MRS2 antibodies?

Several factors can contribute to false positive results:

• Cross-reactivity with other magnesium transporters (particularly other members of the MRS family)

• Non-specific binding to mitochondrial components

• Autofluorescence in certain tissues (particularly problematic in immunofluorescence applications)

• Variable epitope accessibility due to protein conformation or post-translational modifications

To mitigate these issues, always include appropriate controls, verify results with multiple detection methods, and consider validating key findings with alternative approaches such as genetic manipulation or functional assays.

How can MRS2 antibodies be integrated with other research methodologies?

For comprehensive research strategies, MRS2 antibodies can be integrated with:

This multi-method approach provides more robust data than antibody-based detection alone.

What are the challenges in using MRS2 antibodies for neurological disorder research?

When investigating neurological conditions:

• Consider that MRS2 is required for proper myelination in the central nervous system

• Be aware that antibody accessibility to brain tissue may be limited in certain experimental models

• Account for potential expression changes in pathological states that may affect epitope availability

• Distinguish between primary MRS2 dysfunction and secondary changes due to altered mitochondrial function

• Correlate antibody-detected expression changes with functional magnesium transport assays

These considerations are particularly relevant when studying disorders with mitochondrial dysfunction components or magnesium homeostasis disruption.

How do experimental structures of antibody complexes inform MRS2 antibody research?

Recent structural biology research has shown that:

• While computational prediction tools like AlphaFold Multimer can model individual protein heterodimers acceptably, they often fail to properly identify docking sites of antibodies on their targets

• Experimental determination of antibody-antigen complexes provides more accurate binding site information than computational predictions alone

• X-ray crystallography of antibody-antigen complexes helps explain allele specificity and pinpoints critical side chain interactions

• Structural data can reveal conformationally plastic regions of proteins that may influence antibody binding under different conditions

These insights suggest researchers should cautiously interpret computational models of MRS2-antibody interactions and validate with experimental approaches when possible.

What are common technical issues when using MRS2 antibodies and how can they be addressed?

These methodological refinements can significantly improve experimental outcomes when working with MRS2 antibodies.

How do polyclonal and monoclonal MRS2 antibodies compare in research applications?

The choice between antibody types depends on specific research goals:

• Polyclonal antibodies (such as rabbit anti-MRS2): Recognize multiple epitopes, potentially providing stronger signal but may have higher background. Most commercially available MRS2 antibodies are polyclonal .

• Monoclonal antibodies: Offer higher specificity for single epitopes, potentially reducing cross-reactivity but may have reduced sensitivity for detecting low abundance proteins or conformationally altered epitopes.

For critical research requiring absolute specificity, validating findings with both types of antibodies is recommended.

How can neural antibody testing methodologies inform MRS2 antibody research protocols?

General principles from neuronal antibody research can be applied:

• When detecting low-abundance proteins, paired cerebrospinal fluid (CSF) and serum testing may yield more comprehensive results than single-specimen testing

• Interlaboratory reproducibility assessments are essential for validating antibody specificity (kappa values >0.95 represent excellent reliability)

• Multiple testing methodologies (immunohistochemistry, cell-based assays, etc.) may be required for definitive results

• Consideration of sample preparation effects on epitope accessibility is critical, as demonstrated in neural antibody studies where 28% of NMDAR antibodies were detectable only in CSF

These methodological considerations, derived from extensive neural antibody research, can strengthen experimental approaches with MRS2 antibodies.